NCT04440345View on ClinicalTrials.gov

Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity Subjects

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 16, 2020

Primary Completion Date

June 16, 2021

Study Completion Date

August 6, 2021

Conditions

Overweight or Obesity

Interventions

DRUG

IBI362

Administered by subcutaneous injection

DRUG

Placebo

Administered by subcutaneous injection

Trial Locations (1)

Unknown

Peking University people's hospital, Beijing

All Listed Sponsors

lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT04440345 - Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity Subjects | Biotech Hunter | Biotech Hunter